



## COMPANY OVERVIEW

Titan is a pharmaceutical company developing therapeutics utilizing its proprietary long-term drug delivery platform, ProNeura, for the treatment of select chronic diseases for which steady state delivery of a drug provides the potential for an efficacy and/or safety benefit. Titan's lead product in development is an implant for the treatment of moderate-to severe-chronic pruritus.

## RECENT NEWS

### [Titan Announces Positive Results from the First Studies of TP-2021 Implant in an Established Animal Model of Chronic Pruritus](#)

Jun 23 2021, 8:00 AM EDT

### [Titan Pharmaceuticals Announces Filing Of 2020 Annual Report On Form 10-K](#)

Mar 31 2021, 4:30 PM EDT

## STOCK OVERVIEW

Symbol	TTNP
Exchange	Nasdaq
Market Cap	19.33m
Last Price	\$1.96
52-Week Range	\$1.9027 - \$8.85

09/24/2021 04:00 PM EDT

## INVESTOR RELATIONS

Stephen Kilmer  
T: 650-989-2215  
[skilmer@titanpharm.com](mailto:skilmer@titanpharm.com)

## MANAGEMENT TEAM

### **Marc Rubin, MD**

Executive Chairman

### **Kate Beebe DeVarney, Ph.D.**

President and Chief Operating Officer

## TITAN PHARMACEUTICALS, INC.

400 Oyster Point Boulevard  
Suite 505  
South San Francisco, CA 94080-1958  
US

## DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.